Pradaxa (dabigatran)
|
|
- Opal Quinn
- 5 years ago
- Views:
Transcription
1 Pradaxa (dabigatran) Policy Number: Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa when it is determined to be medically necessary because the following criteria are met. When Policy Topic is covered Prior authorization is recommended for prescription benefit coverage of Pradaxa. All approvals are provided for 1 year in duration unless otherwise noted below. Food and Drug Administration (FDA)-Approved Indications 1. Atrial Fibrillation (or Atrial Flutter). Approve for 1 year if the patient has tried Eliquis or Xarelto. Pradaxa is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1 In the RE-LY trial, Pradaxa 150 mg BID significantly reduced the primary composite endpoint of stroke and systemic embolism relative to warfarin in patients with nonvalvular, persistent, paroxysmal or permanent atrial fibrillation with one or more risk factors. 1-2 The 2014 guidelines for nonvalvular atrial fibrillation recommend patients with atrial flutter follow the antithrombotic therapy decisions that are in place for atrial fibrillation. 3 Although not FDA-approved, some evidence suggests that Pradaxa may be useful in patients with atrial fibrillation and valvular heart disease In 2017, the American Heart Association (AHA)/American College of Cardiology (ACC) published a focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. 19 It states that it is reasonable to use direct oral anticoagulants (DOACs) as an alternative to vitamin K antagonist in patients with atrial fibrillation and native aortic valve disease, tricuspid valve disease, or mitral regurgitation and a CHA 2 DS 2 -VASc score of 2 or greater. Patients with native valvular heart disease has been assessed comparing these agents to warfarin. Subgroup analyses have demonstrated that direct oral anticoagulants appear as effective and safe in patients with valvular heart disease as in those without valvular heart disease. Also, the rate of intracranial hemorrhage among patients with DOACs was lower compared with warfarin, regardless of the presence of valvular heart disease. 18 Another review concurred with this recommendation Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Treatment. Approve for 1 year if the patient meets one of the following (A or B): A) The patient has tried Eliquis or Xarelto; OR B) The patient is currently receiving Pradaxa for this condition. Pradaxa is indicated for the treatment of DVT and PE in patients who have been treated with a parenteral anticoagulant for 5 to 10 days. In two trials regarding these clinical scenarios (RE- COVER and RE-COVER II), Pradaxa was non-inferior to warfarin based on the primary composite endpoint of fatal PE or symptomatic non-fatal PE and/or DVT. 1,4
2 3. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), To Reduce the Risk of Recurrence. Approve for 1 year if the patient has tried Eliquis or Xarelto. Pradaxa is indicated to reduce the risk of recurrence of DVT and PE in patients who have been previously treated. Based on trials regarding these scenarios (RE-MEDY and RE-SONATE), Pradaxa was noted to be non-inferior to warfarin and superior to placebo. 1,5 4. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Prophylaxis Following Hip Replacement Surgery. Approve for 60 days if the patient meets one of the following (A or B): A) The patient has tried Eliquis or Xarelto; OR B) The patient is currently receiving Pradaxa for this condition. Pradaxa is indicated for the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery. 1 Based on trials involving patients who had undergone hip replacement surgery (RE-NOVATE and RE-NOVATE II) 6-7 for the prophylaxis of DVT and PE, use of Pradaxa at a dose of 110 mg 1 to 4 hours after surgery followed by 220 mg QD was non-inferior to enoxaparin 40 mg QD. 1 The median duration of use for both medications was 33 days. Allowing 60 days of therapy should be a sufficient time frame to allow for an adequate therapy duration in this scenario. Other Uses with Supportive Evidence 5. Treatment or Prevention of Other Thromboembolic-Related Conditions (e.g., prevention of venous thromboembolism after knee replacement surgery, cancer-associated venous thromboembolic disease). Approve for 6 months if the patient meets ONE of the following criteria (A or B): A) The patient meets one of the following for the condition (i or ii): a. The patient has tried warfarin, fondaparinux, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin, Fragmin [dalteparin injection]); OR b. The patient has tried Eliquis (apixaban tablets) or Xarelto (rivaroxaban tablets); OR B) The patient has been started on Pradaxa for the treatment of an acute thromboembolic condition. Pradaxa has been used in other clinical scenarios (e.g., prophylaxis of DVT and PE after knee replacement surgery) Also, Pradaxa has been used for cancer-associated VTE; however, the National Comprehensive Cancer Network guidelines for cancer-associated VTE (version ) prefer LMWH in these clinical scenarios. 20 Many other medications have been determined to be effective in the treatment of various thromboembolic conditions, as noted in the 2012 American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines for antithrombotic therapy and the prevention of thrombosis 11 as well as in the CHEST Guideline and Expert Panel Report of antithrombotic therapy for VTE disease. 12 The criteria will allow for continuation of therapy for patients who have been started on Pradaxa for an acute thromboembolic condition. In the professional opinion of specialist physicians reviewing the data, we have adopted these criteria. When Policy Topic is not covered Pradaxa has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for noncoverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.) 1. Mechanical Prosthetic Heart Valves (To Prevent Thromboembolic Complications). Pradaxa is contraindicated in patients with mechanical prosthetic heart valves. 1 The safety and efficacy of Pradaxa in patients with a bileaflet mechanical prosthetic heart valve was evaluated in the RE- ALIGN (Randomized, Phase II study to Evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement) study. 1,13-14 RE-ALIGN was terminated early because there were significantly more thromboembolic events (valve thrombosis,
3 stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding in patients randomized to Pradaxa compared to those randomized to warfarin. The FDA recommends that health care professionals should promptly transition any patient with a mechanical heart valve who is receiving Pradaxa to take another medication. 13 Note: If the patient has a mechanical prosthetic heart valve, a history of an acute coronary syndrome (ACS) or coronary artery disease (CAD) [conditions not recommended for approval] but is requesting Pradaxa for another use, approval can be considered if criteria are met. 2. Use After an Acute Coronary Syndrome (ACS) [e.g., unstable angina, non-st elevation myocardial infarction {MI}, or ST elevation MI] to Reduce the Potential for Thrombotic Events (e.g., cardiovascular [CV] death, MI, or stroke). Limited data support the role of Pradaxa at this time. 15 Other alternative, proven, effective, established therapies that are detailed in nationally-recognized guidelines are available for those who have experienced an ACS (e.g., warfarin, heparin, aspirin, clopidogrel, Effient [prasugrel tablets], Brilinta [ticagrelor tablets], and LMWHs) Note: If the patient has a mechanical prosthetic heart valve, a history of an ACS or CAD (conditions not recommended for approval) but is requesting Pradaxa for another use, approval can be considered if criteria are met. Considerations Pradaxa requires prior authorization through the pharmacy services department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers. Description of Procedure or Service Pradaxa is a direct thrombin inhibitor. It has the following indications: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days; to reduce the risk of recurrence of DVT and PE in patients who have been previously treated; and for the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery. 1 Dosing for prophylaxis of DVT and PE after hip replacement surgery is once daily (QD); the recommended dose is twice daily (BID) for all other indications. The most common adverse reactions (> 15%) with Pradaxa are gastritis-like symptoms and bleeding. 1 References 1. Pradaxa capsules [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; November Connolly SJ, Ezekowitz MD, Yusuf S, et al, for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): January CT, Wann LS, Alpert JS, et al AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. Circulation. 2014;130(23): Available at: Accessed on November 30, Schulman S, Kearon C, Kakkar AK, et al, for the RE-COVER Study Group. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24): Schulman S, Kearon C, Kakkar AK, et al, for the RE-MEDY and the RE-SONATE Trials Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):
4 6. Eriksson BI, Dahl OE, Rosencher N, et al, for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet. 2007;370: Eriksson BI, Dahl OE, Huo MH, et al, for the RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomized, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4): Eriksson BI, Dahl OE, Rosencher N, et al, for the RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5: RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs. North American Enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24(1): Burness CD, McKeage K. Dabigatran Etexilate. A review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2012;72(7): Guyatt GH, Akl EA, Crowther M, et al., for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S. Available at: Accessed on November 30, U.S. Food and Drug Administration. FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. Posted 12/19/2012. Available at htm. Accessed on November 30, Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, phase II study to Evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6): Oldgren J, Budaj A, Granger DB, et al, for the RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32: O Gara PT, Kushner FG, Ascheim DD, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):E Available at: Accessed on November 30, Jneid H, Anderson JL, Wright S, et al ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-st elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126: Available at: Access on November 30, 2015.
5 Billing Coding/Physician Documentation Information NA Pharmacy benefit Additional Policy Key Words Policy Number: Policy Implementation/Update Information 06/2014 New Policy titled Pradaxa (dabigatran) 07/2015 Annual review- no changes made 07/2016 Annual review-no changes to policy statement 07/2017 Annual review-no changes to policy statement 07/2018 Annual review no changes to policy State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.
Xarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationProstate Biopsy Alerts
Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: CP.PHAR.225
Clinical Policy: (Fragmin) Reference Number: CP.PHAR.225 Effective Date: 05/16 Last Review Date: 05/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationTransitions of care in anticoagulated patients
Journal of Multidisciplinary Healthcare open access to scientific and medical research Open Access Full Text Article Transitions of care in anticoagulated patients Expert Opinion Franklin Michota Department
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationSupplementary Online Content
Supplementary Online Content Huang W-Y, Singer DE, Wu Y-L, et al. Association of intracranial hemorrhage risk with non vitamin K antagonist oral anticoagulant use vs aspirin use: a systematic review and
More informationAbstract. Introduction. imedpub Journals Doson Chua* Research Article. Cardiovascular Investigations: Open Access
Research Article imedpub Journals www.imedpub.com Cardiovascular Investigations: Open Access Vol. 2 No.1: 1 Use of Non-vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Patients
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationUpdate overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab
Update overview 2018 of reports on direct oral anticoagulants (DOACs) and the antidote idarucizumab Introduction Lareb previously published yearly overviews of reports (most recently in 2017) in consultation
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20131031 New Drug Update Expanding horizons of anticoagulant therapy:
More informationOriginal Policy Date
MP 5.01.15 Newer Oral Anticoagulants Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAnticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017
Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationA technician s guide to new and old oral anticoagulants
By: Jon P. Wietholter, Pharm D, BCPS, Clinical Associate Professor, WVU School of Pharmacy, Internal Medicine Clinical Pharmacist, WVU-Medicine Ruby Memorial Hospital Author Disclosures: Jon P. Wietholter
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationAnticoagulation: a GP primer on the new oral anticoagulants
Cardiology David Brieger Jenny Curnow Anticoagulation: a GP primer on the new oral anticoagulants Background The acceptability of warfarin has been limited by mandatory laboratory monitoring. A number
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationREVIEW ARTICLE. Dabigatran Association With Higher Risk of Acute Coronary Events. Meta-analysis of Noninferiority Randomized Controlled Trials
ONLINE FIRST REVIEW ARTICLE Dabigatran Association With Higher Risk of Acute Coronary Events Meta-analysis of Noninferiority Randomized Controlled Trials Ken Uchino, MD; Adrian V. Hernandez, MD, PhD Background:
More informationTo reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2011 End date of literature
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationClinical Guideline for Anticoagulation in VTE
Clinical Guideline for Anticoagulation in VTE These clinical guidelines are intended to provide evidence-based recommendations regarding the anticoagulation in patients with DVT and PE. Please note that
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More information04/13/2015. Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement. Abbreviations. Learning Objectives TSOACS
1 2 Disclosures Target Specific Oral Anticoagulants (TSOACS) and Areas for Pharmacy Involvement I have nothing to disclose concerning possible financial or personal relationships with commercial entities
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationDirect oral anticoagulants and venous thromboembolism
REVIEW VENOUS THROMBOEMBOLISM Direct oral anticoagulants and venous thromboembolism Massimo Franchini 1 and Pier Mannuccio Mannucci 2 Affiliations: 1 Dept of Transfusion Medicine and Hematology, Carlo
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationPolicy Evaluation: Removal of Prior Authorization on Non-Vitamin K Oral Anticoagulants (NOACS)
Copyright 2012 Oregon State University. All Rights Reserved Research Questions: Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationEliquis and plavix combination therapy
Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationDabigatran etexilate, the prodrug of dabigatran, an oral
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials Jonathan
More informationAmerican College of Cardiology 66th Annual Scientific Session (ACC.17):
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific
More informationNew oral anticoagulants a review
Review article New oral anticoagulants a review 1940 5 BACKGROUND Dabigatran, rivaroxaban and apixaban are three new oral anticoagulants that have recently been approved in Norway. The aim of this article
More informationDabigatran revisited
Dabigatran revisited 22 Dabigatran has been available for general practitioners to prescribe since July, 2011. Twelve months later, over 14 000 patients were being dispensed this medicine. Dabigatran is
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationDisclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationTechnology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327
Dabigatran an etexilate for the treatment and secondary prevention ention of deep vein thrombosis and/or pulmonary embolism Technology appraisal guidance Published: 17 December 2014 nice.org.uk/guidance/ta327
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationHoly Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH
Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationAfter acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationSAVAYSA (edoxaban tosylate) oral tablet
SAVAYSA (edoxaban tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More information